Liraglutide use after weight-loss surgery: 3-year follow-up in everyday care in Chile

Treatment with liraglutide at a median dose of 1.2 mg was associated with a mean weight loss of 5% to 7.7% over three to twelve months following bariatric surgery.

• Weight loss observed at 3, 6, 12, 24, and 36 months was 5%, 7.7%, 7.6%, 5.8%, and 5.1%, respectively.
• The mean reduction in body mass index was 14.8% at 36 months.
• Dropout rates for liraglutide were similar to those seen with typical obesity treatments.
• Approximately 70% of patients were also using other weight-loss medications.
• Liraglutide was well tolerated among participants, though cost barriers led to interruptions in treatment.

Simplified